Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia
Articolo
Data di Pubblicazione:
2019
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
chronic lymphocytic leukaemia; genomic risk factors; ibrutinib; tumour debulking; tumour lysis syndrome risk
Elenco autori:
Wierda, W. G.; Byrd, J. C.; O'Brien, S.; Coutre, S.; Barr, P. M.; Furman, R. R.; Kipps, T. J.; Burger, J. A.; Stevens, D. A.; Sharman, J.; Ghia, P.; Flinn, I. W.; Zhou, C.; Ninomoto, J.; James, D. F.; Tam, C. S.
Link alla scheda completa:
Pubblicato in: